COMMUNIQUÉS West-GlobeNewswire

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

05/03/2024 - 22:30

New preclinical data demonstrating proof-of-concept for the non-signaling gamma-delta T cell CAR (nsCAR) platform candidate targeting CD-33 and CD-123 will be presented. The platform has demonstrated the ability to [...]

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

05/03/2024 - 22:30

BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight [...]

Immunocore presented two posters at CROI 2024

05/03/2024 - 22:30

Immunocore presented two posters at CROI 2024 Preclinical data highlights importance of TCR biology in development of new HIV treatments (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 05 March [...]

Mestag Therapeutics’ M300 Program, Designed to Conditionally Induce Tertiary Lymphoid Structures in Tumors, Selected for Late-Breaking Poster Presentation at AACR Annual Meeting

05/03/2024 - 22:30

CAMBRIDGE, United Kingdom, March 05, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions to develop impactful treatments for patients, [...]

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

05/03/2024 - 22:30

WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally [...]

iSpecimen to Report Full Year 2023 Financial Results on March 13, 2024

05/03/2024 - 22:30

LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”) , an online global marketplace that connects scientists requiring biospecimens for medical research with [...]

23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

05/03/2024 - 22:30

23andMe to give an oral presentation on the genetic signature of ULBP6, the target of 23ME-01473, along with poster presentations of the biology of ULBP6 and mechanism of 23ME-01473, and new non-clinical insights for [...]

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

05/03/2024 - 22:30

Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: [...]

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

05/03/2024 - 22:30

- Investigator-initiated trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma selected for oral presentation SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc [...]

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

05/03/2024 - 22:30

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with [...]

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

05/03/2024 - 22:30

CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis WATERTOWN, Mass., March 05, 2024 [...]

Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression

05/03/2024 - 22:30

Poster presentation: Monday, April 8, 2024, 9:00 am-12:30 p.m. PT UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical- [...]

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

05/03/2024 - 22:30

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting

05/03/2024 - 22:30

Nurix CSO Gwenn M. Hansen, Ph.D., invited as a featured presenter in two separate sessions focused on next-gen degraders and delivering degraders to the site of action SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- [...]

Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

05/03/2024 - 22:30

NEEDHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]

iTeos présentera les données précliniques d’EOS-984, premier médicament de sa catégorie ciblant l’ENT1, lors de l'édition 2024 du congrès annuel de l’Association américaine pour la recherche sur le cancer

05/03/2024 - 22:30

WATERTOWN, Massachusetts et GOSSELIES, Belgique, 05 mars 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), une société biopharmaceutique au stade clinique pionnière dans la découverte et le [...]

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

05/03/2024 - 22:23

SAN FRANCISCO and WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of [...]

LifeScience Logistics Enhances Offerings with Innovative Sampling & Dispensing Suite at Raleigh-Durham Facility

05/03/2024 - 19:36

New cleanroom suite adds secure and compliant pharmaceutical sampling and dispensing offering to world-class pharmaceutical storage and distribution facility in Raleigh-Durham, North Carolina. DALLAS, March 05, 2024 ( [...]

Sandoz receives FDA approval for first and only denosumab biosimilars

05/03/2024 - 19:24

MEDIA RELEASE Wyost ® (denosumab-bddz) and Jubbonti ® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ® * (denosumab) and Prolia ® * (denosumab) FDA approval [...]